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Abstract: A significant proportion of patients with papillary thyroid
cancer (PTC) present with extrathyroidal extension (ETE) and lymph
node metastasis (LNM). However, the molecular mechanism of tumor
invasiveness in PTC remains to be elucidated.
The aim of this study is to understand the role of Hedgehog (Hh)
signaling in tumor aggressiveness in patients with PTC.
Subjects were patients who underwent thyroidectomy from 2012 to
2013 in a single institution. Frozen or paraffin-embedded tumor tissues
with contralateral-matched normal thyroid tissues were collected. Hh
signaling activity was analyzed by quantitative RT-PCR (qRT-PCR)
and immunohistochemical (IHC) staining. Datasets from Gene Expres-
sion Omnibus (GEO) (National Center for Biotechnology Information)
were subjected to Gene Set Enrichment Analysis (GSEA).
BRAFT1799A and telomerase reverse transcriptase promoter mutation
C228T were analyzed by direct sequencing.
Among 137 patients with PTC, glioma-associated oncogene homolog
1 (GLI1) group III (patients in whom the ratio of GLI1 messenger
ribonucleic acid (mRNA) level in tumor tissue to GLI1 mRNA level in
matched normal tissue was in the upper third of the subject population)
had elevated risk for ETE (odds ratio [OR] 4.381, 95%confidence interval
[CI] 1.414–13.569, P¼ 0.01) and LNM (OR 5.627, 95% CI 1.674–
18.913, P¼ 0.005). Glioma-associated oncogene homolog 2 (GLI2)
group III also had elevated risk for ETE (OR 4.152, 95% CI 1.292–
13.342, P¼ 0.017) and LNM (OR 3.924, 95% CI 1.097–14.042,
P¼ 0.036). GSEA suggested that higher GLI1 expression is associatedHyun Nam, MD, P b Shin, MD,
, MD, PhD, and Young Suk Jo, MD, PhD
GLI1 and GLI2 expressions were clearly related to aggressive
clinicopathological features and aberrant activation of GLI1 involved
in the axon guidance pathway. These results may contribute to devel-
opment of new prognostic markers, as well as novel therapeutic targets.
(Medicine 94(25):e998)
Abbreviations: ABLIM3 = actin binding LIM protein family,
member 3, ATC = anaplastic thyroid carcinoma, BCC = basal cell
carcinoma, BRAF = v-raf murine sarcoma viral oncogene homolog
B, CDH1 = E-cadherin, CLND = central lymph node dissection,
DHH = Desert Hedgehog, EMT = epithelial-mesenchymal
transition, EPHA8 = EPH receptor A8, ETE = extrathyroidal
extension, FES = feline sarcoma oncogene, FTA = follicular
adenoma, GLI1 = glioma-associated oncogene homolog 1, GLI2 =
glioma-associated oncogene homolog 2, GSEA = Gene Set
Enrichment Analysis, Hh = Hedgehog, HHIP = Hedgehog-
interacting protein, IHC = immunohistochemical, IHH = Indian
Hedgehog, L1CAM = L1 cell-adhesion molecule, LNM = lymph
node metastasis, MB = medulloblastoma, NFATc4 = nuclear factor
of activated T-cells, cytoplasmic, calcineurin-dependent 4,
PLXNB3 = plexin B3, PTC = papillary thyroid cancer, PTCH =
patched, ROBO3 = roundabout, axon guidance receptor. homolog
3, SEMA3D = sema domain, short basic domain, secreted,
(semaphorin) 3D, SEMA6A = sema domain, cytoplasmic
domain, (semaphorin) 6A, SHH = Sonic Hedgehog, TERT =
telomerase reverse transcriptase, TGFb = transforming growth
factor-b, VIM = vimentin.
INTRODUCTION
P apillary thyroid cancer (PTC) is generally associated withfavorable outcomes. However, lymph node metastasis (LNM)
occurs in 20% to 90%of patients with PTC.1–3 LNM is commonly
associated with locoregional recurrence of PTC.4,5 Therapeutic
central lymph node dissection (CLND) in patients with clinically
diagnosedmetastatic lymph nodes has been accepted as a standard
therapy. However, prophylactic CLND in patients with no clini-
cally detectable metastatic lymph nodes has remained controver-
sial because of the limited therapeutic benefit and the risk of
surgical complications.6,7 Previous reports have attempted to
resolve this controversy by proposing clinical or molecular mar-
kers that might predict LNM and locoregional recurrence, such as,
large tumor size, extrathyroidal extension (ETE), BRAFV600E
mutation, and telomerase reverse transcriptase (TERT) promoter
mutations.8–10
The Hedgehog (Hh) signaling pathway is an evolutionarily
conserved system that is essential for patterning and organo-
genesis during embryonic development.11–14 The central com-alian Hh pathway include 3 secretory
g (SHH), Desert Hedgehog (DHH), and
); patched (PTCH), a receptor involved
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in the negative regulation of the pathway; Hedgehog-interacting
protein (HHIP), a negative regulation factor; and the glioma-
associated oncogene (GLI) transcription factors [glioma-associ-
ated oncogene homolog 1 [GLI1], glioma-associated oncogene
homolog 2 [GLI2], and GLI family zinc finger 3 (GLI3)].15
Recently, aberrant activation of the Hh signaling pathway has
been linked with tumorigenesis in medulloblastoma (MB) and
basal cell carcinoma (BCC).16,17 In addition, hyperactive Hh
signaling has been reported in pancreatic, colon, gastric, lung,
breast, and prostatic cancers, as well as leukemia and multiple
myeloma.18,19
In this study, we measured the messenger ribonucleic acid
(mRNA) expression levels of the central components of the Hh
signaling pathway in patients with PTC. Mean mRNA levels of
Hh signaling components in PTC were lower than the corre-
sponding levels in matched normal thyroid tissues. However,
patients with PTC expressing higher levels of GLI1 and GLI2
mRNA frequently presented with ETE and LNM. In addition,
Gene Set Enrichment Analysis (GSEA) revealed that GLI1
expression was coordinately regulated with genes involved in
axon guidance, as verified by quantitative RT-PCR (qRT-PCR)
and immunohistochemical (IHC) staining.
MATERIALS AND METHODS
Subjects and Clinical Data
We enrolled 137 patients (21 men and 116 women) who
underwent thyroidectomy for the management of conventional
PTC between January 2012 and December 2013 at Severance
Hospital, Yonsei Cancer Center, Seoul, South Korea. For a
validation set, we also collected 103 patients independently
(21 men and 82 women). The baseline clinicopathological
characteristics of derivation and validation cohort are summar-
ized in supplementary Table 1, http://links.lww.com/MD/A305.
All of the samples were microscopically dissected at the time of
surgery after confirmation of tissue diagnosis from frozen
section, validated by hematoxylin–eosin staining after the
operation. Samples were taken from the central part of the
cancer and from histologically normal tissue. On histological
examination,>90% of the cells were thyroid cancer cells. All of
the patients provided informed consent before study participa-
tion, and the study protocol was approved by the institutional
review board of Severance Hospital.
DNA Isolation and Sequencing
Genomic DNA from paraffin-embedded thyroid tissue
specimens was prepared using QIAamp DNA Formalin-fixed,
paraffin-embedded Tissue Kit (Qiagen, Venlo, The Nether-
lands). Exon 15 of the BRAF gene was amplified by Polymerase
chain reaction (PCR) with the following primers: forward 50-
ATGCTTGCTCTGATAGGAAA-30 and reverse 50-ATT TTT
GTG AATACT GGG GAA-30.20 For TERT promoter contain-
ing the hotspots of C228T and C250T, mutations was amplified
using primers: forward 50-AGT GGA TTC GCG GGC ACA
GA-30 and reverse 50-CAG CGC TGC CTG AAA CTC-30.10
The purified PCR products were sequenced on an ABI PRISM
3100 automated capillary DNA Sequencer, Foster City, CA
using the BigDye Terminator Cycle Sequencing Ready Reac-
tion Kit (Applied Biosystems, Foster City, CA).
Lee et alRNA Isolation and Real-Time PCR
Total RNA was extracted from fresh frozen tissues using
Trizol (Invitrogen, Carlsbad, CA), and the RNA quality was
2 | www.md-journal.comverified by using Agilent’s 2100 Bioanalyzer System (Agilent
Technologies, Santa Clara, CA) as shown in supplementary
Figure 1, http://links.lww.com/MD/A305. Complementary
DNA (cDNA) was prepared from total RNA using Moloney
Murine Leukemia Virus Reverse Transcriptase (Invitrogen) and
oligo-dT primers (Promega, Madison, WI). qRT-PCR was per-
formed on the cDNA using the QuantiTect SYBRGreen RT-PCR
Kit (Qiagen,Valencia, CA). Primers used in qRT-PCR are listed in
supplementary Table 2, http://links.lww.com/MD/A305. Relative
expression was calculated using the StepOne Real-Time PCR
System (Applied Biosystems). qRT-PCR experiments were
repeated3 times, and each experimentwas performed in triplicate.
GSEA of GLI1-Correlated Genes
Microarray data from theGene Expression Omnibus (GEO)
ofNational Center for Biotechnology Information (NCBI) (Data-
Set Record GDS1732 and GSE33630 for PTC, GSE16515 for
pancreatic cancer) were subjected to GSEA.21 Genes whose
expression was strongly correlated to GLI1, or that were inter-
esting for other reasons, were selected for validation by qRT-PCR
using cDNA derived from our subjects. To verify our GSEA, the
public data from The Cancer Genome Atlas Research Network
has been subjected to statistical analyses [The Cancer Genome
Atlas (TCGA), http://cancergenome.nih.gov].22
IHC Analysis
Paraffin-embedded tissue sections (4 mm thick) were
deparaffinized in xylene and rehydrated in a graded series of
ethanol (100%–80%). Antigens were retrieved in 0.01 M citrate
buffer (pH 6.0) by heating the tissue sections in an autoclave
(CHS-ACCE-860, Choong Wae Medical Corporation, Korea).
The tissue sections were then placed in 3% hydrogen peroxide
for 5 minutes to inactivate endogenous peroxidases and then
blocked for 10 minutes with normal horse serum (UltraTech
HRP kit; Immunotech, Marseille, France). The primary anti-
bodies used for this study were anti-Gli1 (sc-20687; Santa Cruz
Biotechnology, Santa Cruz, CA), anti-NFATc4 (sc-32985; Santa
Cruz Biotechnology), anti-ABLIM3 (HPA003245, Sigma, St
Louis, MO), and anti-FES (HPA-001376, Sigma). Sections were
incubated for 60 minutes with appropriately diluted primary
antibodies, incubated with biotinylated secondary antibody for
20 minutes, and then visualized with UltraTech HRP, strepta-
vidin peroxidase (Immunotech) and aminoethylcarbazole
solution for a further 10 minutes. Finally, the tissue sections
were counterstained with hematoxylin for 10 seconds. All
incubations were performed at room temperature.
Statistical and Graphical Analysis
Differences between means were analyzed by Mann–
Whitney U test, paired t test, independent samples t test, or
1-way Analysis of variance, as indicated in figure and table
legends. Comparisons between groups were performed by x2 or
linear-by-linear association. All analyses were performed using
SPSS version 18.0 for Windows (SPSS Inc, Chicago, IL) or
GraphPad Prism (GraphPad Software, Inc, San Diego, CA). All
reported P values are 2-sided.
RESULTS
mRNA Expression of Central Components of the
Medicine  Volume 94, Number 25, June 2015Hh Pathway is Reduced in PTC
Initially, we performed qRT-PCR and calculated the
relative mRNA expression of each central component of the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
(r¼ 0.12, P¼ 0.17). Taken together, these data suggest that
GLI1, GLI2, and HHIP are coordinately regulated by a nega-
tive-feedback loop in normal thyroid tissues. By contrast, in
FIGURE 1. Comparison between PTC and matched normal thyroid tissues of mRNA expression of central components of Hh pathways:
(G)
Des
g,
er,
FIGURE 2. Correlation between expression levels of the central
components of the Hh pathway. (A and B) Correlation between
GLI1 and HHIP relative mRNA expression in normal thyroid tissues
(A) and PTC (B). (C and D) Correlation between GLI2 and HHIP
relativemRNAexpression in normal thyroid tissues (C) and PTC (D).
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internal control gene GAPDH. In this step, we used tumor and
contralateral matched normal samples from 137 patients with
PTC. As shown in Figure 1A, relativemRNA expression ofGLI1
in normal thyroid tissue was 1.73 0.06. In PTC, GLI1 mRNA
expression in PTC was statistically significantly reduced
(0.88 0.04; paired t test, P< 0.001). The other central com-
ponents of the Hh pathway, including GLI2, GLI3, HHIP,
PTCH1, SHH, DHH, and IHH, exhibited the same expression
patterns, with significantly lower levels in PTC than in matched
normal tissues (Figure 1B–H). Thus, our qRT-PCR data
suggested that the Hh pathway activity might be generally
reduced in PTC.
Relationship Between GLI1/GLI2 and HHIP
Expression in Normal Thyroid Tissues and PTC
Three of the genes analyzed, GLI1, GLI2, and HHIP, are
regarded as targets of the Hh pathway.14 To verify whether the
GLI1-dependent transcriptional activities of these target genes
are coordinately regulated in normal thyroid tissue and PTC, we
analyzed the correlation between the mRNA expression levels
of HHIP and GLI1 or GLI2. In normal thyroid tissues, we found
a strong positive correlation between levels of GLI1 and HHIP
mRNA levels (r¼ 0.55, P< 0.001), indicating that the nega-
tive-feedback loop of Hh pathway is functioning normally in
normal thyroid tissues via expression of HHIP (Figure 2A).
However, the correlation between GLI1 and HHIP mRNAs
GLI1 (A), GLI2 (B), GLI3 (C), HHIP (D), PTCH1 (E), SHH (F), DHH
meansSEM. P<0.05, P<0.01, and P<0.001. DHH¼
GLI2¼glioma-associated oncogene homolog 2, Hh¼Hedgeho
mRNA¼Messenger ribonucleic acid, PTC¼papillary thyroid cancdisappeared in PTC (Figure 2B). Likewise, expression of GLI2
(Figure 2C and D) was also positively correlated with that of
HHIP in normal tissues (r¼ 0.17, P¼ 0.05) but not in PTC
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved., and IHH (H). Means were compared by paired t test. All data are
ert Hedgehog, GLI1¼glioma-associated oncogene homolog 1,
HHIP¼Hedgehog-interacting protein, IHH¼ Indian Hedgehog,
PTCH¼patched, SHH¼Sonic Hedgehog.Linear correlations between 2 groups were analyzed by Pearson R
correlation test. GLI1¼glioma-associated oncogene homolog 1,
Hh¼Hedgehog, HHIP¼Hedgehog-interacting protein, mRNA¼
Messenger ribonucleic acid, PTC¼papillary thyroid cancer.
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TABLE 1. Analyses of Clinicopathological Parameters and mRNA Expression of the Central Components of the Hh Pathway,
According to Presence or Absence of ETE
Extrathyroidal Extension
Absent (n¼ 68) Present (n¼ 69) P
Age, y, meanSD 46.1 11.7 47.5 14.9 0.528
Sex (female) 58 (85.3) 58 (84.1) 0.841y
Tumor size, cm, meanSD 2.2 1.0 2.2 0.8 0.840
Multifocality 0.001y
Absent 62 (91.2) 51 (73.9)
Unilateral 6 (8.8) 4 (5.8)
Bilateral 0 (0) 14 (20.3)
LNM 0.001y
Absent 37 (54.4) 22 (31.9)
Central 30 (44.1) 37 (53.6)
Lateral 1 (1.5) 10 (14.5)
Distant metastasis 0.321y
Absent 68 (100) 68 (98.6)
Present 0 (0) 1 (1.4)
TNM stage 0.001y
I 35 (55.9) 28 (40.6)
II 15 (22.1) 1 (1.4)
III 1 (1.5) 7 (10.1)
IV 14 (20.6) 33 (47.8)
GLI1 0.002y
I 31 (45.6) 15 (21.7)
II 21 (30.9) 25 (36.2)
III 16 (23.5) 29 (42.0)
GLI2 0.005y
I 31 (45.6) 15 (21.7)
II 20 (29.4) 26 (37.7)
III 17 (25.0) 28 (40.6)
GLI3 0.250y
I 26 (38.2) 20 (29.0)
II 22 (32.4) 24 (34.8)
III 20 (29.4) 25 (36.2)
HHIP 0.916y
I 22 (32.4) 24 (34.8)
II 25 (36.8) 21 (30.4)
III 21 (30.9) 24 (34.8)
PTCH1 0.755y
I 23 (33.8) 23 (33.3)
II 21 (30.9) 25 (36.2)
III 24 (35.3) 21 (30.4)
SHH 0.920y
I 22 (32.4) 26 (37.7)
II 27 (39.7) 21 (30.4)
III 19 (27.9) 22 (31.9)
DHH 0.465y
I 21 (30.9) 25 (36.2)
II 23 (33.8) 23 (33.3)
III 24 (35.3) 21 (30.4)
IHH 0.916y
I 22 (32.4) 24 (34.8)
II 25 (36.8) 21 (30.4)
III 21 (30.9) 24 (34.8)
BRAF T1799A mutation
Absent 24 (35.3) 16 (23.2) 0.119y
Present 44 (64.7) 53 (76.8)
Lee et al Medicine  Volume 94, Number 25, June 2015
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95% CI 0.102–0.759).
To validate our data, we performed an independent
analysis for 103 patients with conventional PTC. In this
TABLE 2. Multivariate Analysis of the Association of ETE With
GLI1 and GLI2 mRNA Expression Level
ETE
OR 95% CI P
GLI1 group III

3.701 1.550–8.837 0.003
GLI1 group IIIy 3.340 1.204–9.269 0.021
GLI1 group IIIz 3.989 1.345–11.836 0.013
GLI1 group III§ 4.381 1.414–13.569 0.01
GLI2 group III

3.392 1.430–8.043 0.006
GLI2 group IIIy 3.496 1.242–9.839 0.018
GLI2 group IIIk 4.028 1.276–12.720 0.018
GLI2 group III 4.152 1.292–13.342 0.017
CI¼ confidence interval, DHH¼Desert Hedgehog,
ETE¼ extrathyroidal extension, GLI1¼ glioma-associated oncogene
homolog 1, HHIP¼Hedgehog-interacting protein, IHH¼ Indian
Hedgehog, mRNA¼Messenger ribonucleic acid, OR¼ odds ratio,
PTCH¼ patched, SHH¼Sonic Hedgehog, TERT¼ telomerase reverse
transcriptase.
Adjusted for age and sex.
y In addition to adjustment, adjusted for multiplicity, tumor size, N
stage and TNM stage.
z In addition to adjustment y, adjusted forGLI2,GLI3,HHIP, PTCH1,
SHH, DHH, and IHH mRNA levels.
§ In addition to adjustment z, adjusted for BRAF 1799A and TERT
C228T mutations.k In addition to adjustment z, adjusted forGLI1,GLI3,HHIP, PTCH1,
Extrathyroidal Extension
Absent (n¼ 68) Present (n¼ 69) P
TERT promoter C228T mutation
Absent 64 (94.1) 64 (92.8) 0.747y
Present 4 (5.9) 5 (7.2)
Unless stated otherwise, data represent and followed by the corresponding percentage of total (in parentheses). DHH¼Desert Hedgehog,
ETE¼ extrathyroidal extension, GLI1¼ glioma-associated oncogene homolog 1, Hh¼Hedgehog, HHIP¼Hedgehog-interacting protein,
IHH¼ Indian Hedgehog, LNM¼ lymph node metastasis, mRNA¼Messenger ribonucleic acid, PTCH¼ patched, SHH¼Sonic Hedgehog,
f M
Medicine  Volume 94, Number 25, June 2015 GLI1 Expression in Papillary Thyroid CancersPTC, this negative-feedback loop might be dysregulated, or the
GLI transcriptional factors might be induced independently of
the canonical Hh pathway.
Relationship Between Expression of Hh Pathway
Components and Clinicopathological
Parameters
To determine the clinical implications of mRNA expression
levels of the central Hh pathway components, we classified the
study patients into 3 groups according to the ratio of mRNA
expression in tumors versus normal tissue (ie, relative mRNA
expression in PTC/relativemRNA expression inmatched normal
tissue): group I, lowest one third (n¼ 46); group II, middle one
third (n¼ 46); group III, highest one third (n¼ 45, supplementary
Figure 2, http://links.lww.com/MD/A305). In the initial statisti-
cal analysis of the effect of GLI1 mRNA expression on clinico-
pathological parameters (supplementary Table 3, http://
links.lww.com/MD/A305), GLI1 group III presented with more
frequent ETE (P¼ 0.002) and LNM (P< 0.001). Interestingly,
GLI1 group III also indicated more frequent TERT promoter
C228T mutation (supplementary Figure 3, http://links.lww.com/
MD/A305 and supplementary Table 2, http://links.lww.com/
MD/A305). Furthermore, as shown in supplementary Table 4 ,
http://links.lww.com/MD/A305, GLI2 group III also exhibited
more frequent ETE (P¼ 0.005) and LNM (P¼ 0.005). By con-
trast, HHIP group III exhibited less frequent LNM (supple-
mentary Table 5, http://links.lww.com/MD/A305, P¼ 0.025).
Taken together, these data suggest that the expression of the
zinc-finger transcription factorsGLI1 andGLI2, aswell asHHIP,
a vertebrate-specific inhibitor ofHh signaling,might play import-
ant roles in ETE and LNM. The implication here is that Hh
signaling contributes to tumor aggressiveness in PTC.
Impact of the Central Components of the Hh
Pathway on ETE and LNM
To determine the factors affecting ETE and LNM in our
study patients, we performed statistical analyses of clinicopatho-
logical parameters and mRNA expression of the central com-
ponents of the Hh pathway, according to the presence or absence
of ETE and LNM. As shown in Table 1, ETE was associated with
multifocality (P¼ 0.001), LNM (P¼ 0.001), TNMClassification
ofMalignant Tumours (TNM) stage (P¼ 0.001),GLI1 expression
(P¼ 0.002), andGLI2 expression (P¼ 0.005). Remarkably,GLI1
group III was a strong positive predictor of ETE after adjusting for
clinicopathological parameters, expression of Hh pathway com-
TERT¼ telomerase reverse transcriptase, TNM¼TNM Classification o
P values were calculated by Student t test.
yP values were calculated by x2 or linear-by-linear association.ponents, the mutation status of BRAFT1799A and TERT pro-
moter (Table 2; odds ratio [OR] 4.381, 95% confidence interval
[CI] 1.414–13.569,P¼ 0.01) comparedwith group I. In the same
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.multivariate analyses,GLI2 group III was also a positive predictor
of ETE (Table 2; OR 4.152, 95% CI 1.292–13.342, P¼ 0.017).
In the analyses of LNM (Table 3), several factors were
identified as predictors: ETE (P¼ 0.003), TNM stage
(P¼ 0.005), GLI1 (P< 0.001), GLI2 (P¼ 0.005), and HHIP
(P¼ 0.025); all except HHIP were positive predictors. In multi-
variate analyses (Table 4), GLI1 group III was the strongest
positive predictor of LNM (P¼ 0.005, OR 5.627, 95% CI
1.674–18.913) compared with group I, and GLI2 group III
was also a strong positive indicator (P¼ 0.036, OR 3.924, 95%
CI 1.097–14.043). Additionally, HHIP group III was a statisti-
cally significant negative predictor of LNM, even after adjust-
ing for clinicopathological parameters (P¼ 0.012, OR 0.278,
alignant Tumours.SHH, DHH, and IHH mRNA levels.
 In addition to adjustment k, adjusted for BRAF T1799A and TERT
promoter C228T mutation.
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TABLE 3. Analyses of Clinicopathological Parameters and mRNA Expression of the Central Components of Hh Pathway,
According to Presence or Absence of LNM
LNM
Present (n¼ 78) (%)
No. (n¼ 59) (%) Central LN (n¼ 67) (%) Lateral LN (n¼ 11) (%) P
Age, y, meanSD 46.1 12.7 48.0 12.6 43.6 20.7 0.517
Sex (female) 54 (91.5) 53 (79.1) 9 (81.8) 0.098y
Tumor size, cm, meanSD 2.4 0.9 2.1 0.9 2.2 0.9 0.217
Multifocality 0.095y
Absent 51 (86.4) 54 (80.6) 8 (72.7)
Unilateral 2 (3.4) 8 (11.9) 0 (0)
Bilateral 6 (10.2) 5 (7.5) 3 (27.3)
ETE
Limited to thyroid 37 (62.7) 30 (44.8) 1 (9.1) 0.003y
Presence 22 (37.3) 37 (55.2) 10 (90.9)
Distant metastasis 0.514y
Absent 58 (98.3) 67 (100) 11 (100)
Present 1 (1.7) 0 (0) 0 (0)
TNM stage 0.005y
I 32 (54.2) 27 (40.3) 7 (63.6)
II 15 (25.4) 1 (1.5) 0 (0)
III 7 (11.9) 0 (0) 1 (9.1)
IV 5 (8.5) 39 (58.2) 3 (27.3)
GLI1 <0.001y
I 26 (44.1) 20 (29.9) 0 (0)
II 21 (35.6) 23 (34.3) 2 (18.2)
III 12 (20.3) 24 (35.8) 9 (81.8)
GLI2 0.005y
I 24 (40.7) 21 (31.3) 1 (9.1)
II 21 (35.6) 23 (34.3) 2 (18.2)
III 14 (23.7) 23 (34.3) 8 (72.7)
GLI3 0.466y
I 19 (32.2) 23 (34.3) 4 (36.4)
II 17 (28.8) 26 (38.8) 3 (27.3)
III 23 (39.0) 18 (26.9) 4 (36.4)
HHIP 0.025y
I 14 (23.7) 26 (38.8) 6 (54.5)
II 20 (33.9) 25 (37.3) 1 (9.1)
III 25 (42.4) 16 (23.9) 4 (36.4)
PTCH1 0.574y
I 21 (35.6) 22 (32.8) 3 (27.3)
II 15 (25.4) 25 (37.3) 6 (54.5)
III 23 (39.0) 20 (29.9) 2 (18.2)
SHH 0.939y
I 15 (25.4) 29 (43.3) 4 (36.4)
II 29 (49.2) 18 (26.9) 1 (9.1)
III 15 (25.4) 20 (29.9) 6 (54.5)
DHH 0.074y
I 25 (42.4) 19 (28.4) 2 (18.2)
II 19 (32.2) 21 (31.3) 6 (54.5)
III 15 (25.4) 27 (40.3) 3 (27.3)
IHH 0.821y
I 20 (33.9) 22 (32.8) 4 (36.4)
II 19 (32.2) 23 (34.3) 4 (36.4)
III 20 (33.9) 22 (32.8) 3 (27.3)
BRAF T1799A mutation
Absent 17 (28.8) 20 (29.9) 3 (27.3) 0.996y
Present 42 (71.2) 47 (70.1) 8 (72.7)
Lee et al Medicine  Volume 94, Number 25, June 2015
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LNM
Present (n¼ 78) (%)
No. (n¼ 59) (%) Central LN (n¼ 67) (%) Lateral LN (n¼ 11) (%) P
TERT promoter C228T mutation
Absent 57 (96.6) 60 (89.6) 11 (100) 0.525y
Present 2 (3.4) 7 (10.4) 0 (0)
Unless stated otherwise, data represent and followed by the corresponding percentage of total (in parentheses). ANOVA¼Analysis of variance,
DHH¼Desert Hedgehog, ETE¼ extrathyroidal extension, GLI1¼ glioma-associated oncogene homolog 1, Hh¼Hedgehog, HHIP¼Hedgehog-
interacting protein, IHH¼ Indian Hedgehog, LN¼Lymph node, LNM¼ lymph node metastasis, mRNA¼Messenger ribonucleic acid,
tran
Medicine  Volume 94, Number 25, June 2015 GLI1 Expression in Papillary Thyroid Cancersvalidation set, GLI1 group III was consistently related to ETE
(P< 0.001) and LNM (P< 0.001) (supplementary Table 6,
http://links.lww.com/MD/A305).
Strong Correlation of GLI1 Expression With Axon
PTCH¼ patched, SHH¼Sonic Hedgehog, TERT¼ telomerase reverse
P values were calculated by 1-way ANOVA.
yP values were calculated by x2 or linear-by-linear association.Guidance Gene Set
To obtain further insight into the mechanisms of GLI1
action, we performed GSEA using data from a public repository,
TABLE 4. Multivariate Analysis of the Association of LNMWith
GLI1, GLI2, and HHIP mRNA Levels
LNM (N1)
OR 95% CI P
GLI1 group III

3.723 1.515–9.148 0.004
GLI1 group IIIy 4.568 1.603–13.111 0.004
GLI1 group IIIz 5.780 1.779–18.779 0.004
GLI1 group III§ 5.627 1.674–18.913 0.005
GLI2 group III

2.423 1.013–5.793 0.047
GLI2 group IIIy 1.842 0.694–4.890 0.220
GLI2 group IIIk 3.949 1.105–14.107 0.034
GLI2 group III 3.924 1.097–14.043 0.036
HHIP group III

0.351 0.145–0.850 0.02
HHIP group IIIy 0.278 0.102–0.759 0.012
HHIP group III# 0.239 0.049–1.158 0.075
HHIP group III

0.214 0.043–1.072 0.061
CI¼ confidence interval, DHH¼Desert Hedgehog,
ETE¼ extrathyroidal extension, GLI1¼ glioma-associated oncogene
homolog 1, HHIP¼Hedgehog-interacting protein, IHH¼ Indian
Hedgehog, LNM¼ lymph node metastasis, mRNA¼Messenger ribo-
nucleic acid, OR¼ odds ratio, PTCH¼ patched, SHH¼Sonic Hedge-
hog, TERT¼ telomerase reverse transcriptase.
Adjusted for age and sex.
y In addition to adjustment , adjusted for ETE, multiplicity, tumor
size and TNM stage.
z In addition to adjustment y, adjusted forGLI2,GLI3,HHIP, PTCH1,
SHH, DHH, and IHH mRNA levels.
§ In addition to adjustment z, adjusted for BRAF 1799A and TERT
C228T mutations.k In addition to adjustment y, adjusted forGLI1,GLI3,HHIP, PTCH1,
SHH, DHH, and IHH mRNA levels.
 In addition to adjustment k, adjusted for BRAF 1799A and TERT
C228T mutations.
# In addition to adjustment y, adjusted for GLI1, GLI2, GLI3, PTCH1,
SHH, DHH, and IHH mRNA levels.
In addition to adjustment #, adjusted for BRAF T1799A and TERT
promoter C228T mutation.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.NCBIGEO. The dataset GDS1732 contained expression profiles
from 7 normal thyroid tissues and matched PTC specimens (14
total samples). In this dataset,GLI1 expression was quite hetero-
geneous in normal and tumor tissues (supplementary Figure 4A,
http://links.lww.com/MD/A305); moreover, GSEA revealed no
enrichment in genes associated with theHh pathway in normal or
PTC (supplementary Figure 4B, http://links.lww.com/MD/
A305). However, when we performed GSEA on the samples
with the lowest GLI1 expression (group 1: GSM85223 and
GSM85225) and those with the highest GLI1 expression (group
2: GSM85222 and GSM85224), we observed that the top 20
KEGG gene sets enriched in group 2 included sets related to cell
interaction and migration, for example, neuroactive ligand–
receptor interaction, leukocyte transendothelial migration, cyto-
kine and cytokine receptor interaction, and the Notch signaling
pathway (supplementary Table 7, http://links.lww.com/MD/
A305). In addition, the gene set ‘‘axon guidance’’ was signifi-
cantly enriched in group 2 (supplementary Figure 5, http://links.
lww.com/MD/A305; ES¼0.38328, nominal P value¼
0.005165, false discovery rate q-value¼ 0.235033), indicating
that GLI1 might increase the migration and invasion abilities of
PTC by inducing expression of genes related to axon guidance.
Furthermore, the dataset GSE33630 contained expression pro-
files from 45 normal thyroid tissues; 49 PTC and 11 anaplastic
thyroid carcinoma (ATC) specimens (105 total samples) showed
the enrichment ofHh signaling pathway in normal thyroid tissues
(supplementary Figure 6, http://links.lww.com/MD/A305).
However, when we selected 16 cases of high GLI1 expression
(high GLI1 group) and 16 cases of low GLI1 expression (low
GLI1 group) and performed the GSEA using those 2 groups, the
gene sets related to axon guidance were consistently enriched in
high GLI1 group (Figure 3A). Because the classic targets of Hh
pathways such asGLI1,GLI2, andHHIP have been discovered in
humanpancreatic cancers,weperformedGSEAusingGSE16515
derived from pancreatic cancers.23 Compatible with our GSEA
data using GDS1732 and GSE33630, the gene set encompassing
the axon guidance was significantly enriched in pancreatic
cancers with high GLI1 expression (supplementary Figure 7,
http://links.lww.com/MD/A305). To validate the results of our
GSEA, we performed qPCR, using cDNA derived from GLI1
groups I (n¼ 7) and III (n¼ 7), to detect mRNAs encoding actin
binding LIM protein family, member 3 (ABLIM3); nuclear factor
of activated T-cells, cytoplasmic, calcineurin-dependent 4
(NFATc4); L1 cell-adhesion molecule (L1CAM); sema domain,
immunoglobulin domain, short basic domain, secreted, (sema-
scriptase, TNM¼TNM Classification of Malignant Tumours.phorin) 3D (SEMA3D); feline sarcoma oncogene (FES); plexin
B3 (PLXNB3); sema domain, transmembrane domain, and cyto-
plasmic domain, (semaphorin) 6A (SEMA6A); roundabout, axon
www.md-journal.com | 7
FIGURE 3. Relationship between expression levels ofGLI1 and the KEGG axon guidance gene set. (A) GSEA using gene expression profiles
selected from NCBI GEO Record GSE33630. (B and C) qRT-PCR analysis for representative axon guidance genes in 7 patients each from
GLI1 groups I (ratio ofGLI1 expression in PTC vs normal tissues in the lowest one third of all patients) and III (ratio in the highest one third).
All
  
gen
Lee et al Medicine  Volume 94, Number 25, June 2015guidance receptor, homolog 3 (ROBO3); EPH receptor A8
(EPHA8). As expected, expression of all those axon guidance-
relatedmRNAswas higher in group III than in group I (Figure 3B
and C). In addition, IHC staining of paraffin-embedded tumor
samples from the same patients used for the qRT-PCR analysis
revealed that NFATc4, ABLIM3, and FES expressions are
increased in high GLI1 PTC (Figure 4). Taken together, these
data indicate that GLI1 expression is consistently associated with
elevated aberrant expression of axon guidance genes.24,25 In
addition, the correlation analyses using GSE33630,GLI2mRNA
expression showed a negative relationship with E-cadherin
(CDH1) mRNA expression and a positive relationship with
vimentin (VIM). Moreover, HHIP mRNA expression showed a
negative relationship with VIM (data not shown) indicating GLI
and HHIP expression might be also linked to these informative
markers of the epithelial-mesenchymal transition (EMT).
Validation Analyses Using the Public Data From
the Cancer Genome Atlas Research Network
To verify our GSEA results, we performed additional
analyses using the TCGA public data. As shown in Figure 5,
the GLI1 and GLI2 mRNA expressions showed statistically
significant positive correlation with the expressions of axon
Means were compared and analyzed by Mann–Whitney U test.
GEO¼Gene Expression Omnibus, GLI1¼glioma-associated onco
papillary thyroid cancer, qRT-PCR¼quantitative RT-PCR.guidance genes such as ABLIM3, L1CAM, FES, PLXNB3,
SEMA6A, SEMA6B, and ROBO3. Interestingly, the mRNA
expressions of the EMT markers such as E-cadherin (CDH1)
8 | www.md-journal.comand VIM were exactly correspond to our idea (Figure 5H, I, S
and T), but the expressions of AKT1 and mTOR1 were not
related with the GLI1 mRNA expression (Figure 5J and K). In
the validation of clinical data results, the TCGA public data
indicated consistently that the GLI1 and GLI2 mRNA
expressions can affect the clinical tumor progression (Table 5).
DISCUSSION
ETE and LNM are important clinical and histological
indicators that predict locoregional recurrence in patients with
PTC. To date, however, the molecular details of the roles played
by these 2 factors in PTC have remained unclear. One of the
signature molecular mechanisms of tumor progression is
EMT.26 Indeed, stem-like properties of cancer cells have been
implicated in local invasion and metastasis.27 Consistent with
this, expression levels of the EMT-associated factors Slug and
Twist1 are elevated in thyroid cancers.28,29 In addition, over-
expression of VIM, transforming growth factor-b (TGFb), NF-
kB, and integrin has been observed in invasive fronts of
PTC.30–33 However, most studies of EMT have been performed
in cell lines or tissues derived from ATC, and extensive
verification of new EMT markers using clinical samples has
not been performed.
data are means SEM, P<0.05, P<0.01, and P<0.001.
e homolog 1, GSEA¼Gene Set Enrichment Analysis, PTC¼pa-Over the last 2 decades, many studies have mechanistically
investigated the roles of aberrant activation or constitutive
activation of the Hh pathway in cancer progression.14
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FIGURE 4. Representative IHC staining analysis for GLI1, NFATc4, ABLIM3, and FES in PTC from 1 patient in GLI1 group I and 2 patients
LI1
BL
1,
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BCC and MB.17,34 In addition, gain-of-function mutations in
smoothened, frizzled class receptor (SMO), a G-protein-
coupled receptor-like molecule that positively regulates Hh
signaling, have also been detected in BCC, MB, and even in
meningiomas.35 Ligand-dependent activation mechanism may
also be important. For example, autocrine activation of the Hh
pathway in tumor cells has been reported in cancers of the lung,
breast, stomach, and prostate.36–39 Moreover, the Hh pathway
may contribute to the maintenance and differentiation of cancer
stem cells through ligand-dependent mechanisms.40
In this study, we compared relative mRNA expression of
central components of the Hh pathway between PTC and
matched normal tissues. These experiments revealed that
PTC specimens expressed lower levels of the GLI1, GLI2,
GLI3, HHIP, PTCH1, SHH, DHH, and IHH mRNAs than the
corresponding matched normal tissues, suggesting that Hh
pathway activity is reduced in PTC. In general, the zinc-finger
transcription factor GLI1 and GLI2 act as the final effectors of
upstream signaling pathways by inducing the expression of
various genes in a context-specific manner. Hh target genes
include GLI1, PTCH1, and HHIP. Although our qRT-PCR data
did not demonstrate any relationship between GLI1 and PTCH1
expression levels in normal thyroid tissues (data not shown), we
did observe a strong positive correlation between GLI1 and
HHIP levels, indicating that the physiologically relevant nega-
classified into GLI1 group III (original magnification200). In lowG
GLI1 PTC, GLI1, and NFATc4 are mainly detected in the nucleus. A
sarcoma oncogene, GLI1¼glioma-associated oncogene homologtive-feedback loop is operational in normal follicular cells.
However, this relationship disappeared in PTC, suggesting that
the negative-feedback loop might be dysregulated in these cells,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.or alternatively that GLI1 expression is transcriptionally
regulated independently of Hh signaling in these tumors
PTC.41 Supporting our data, 2 NCBI DataSet Records
(GDS1732 and GSE33630) did not show any correlation
between GLI1 and HHIP expression in thyroid tumor tissues
(data not shown).
Recently, BRAFV600E andTERT promotermutations have
been suggested to cooperatively identify recurrent PTC.42 In our
study, GLI1 group III has more frequent TERT promoter C228T
mutation. However, in our study, the prevalence (6.6%) of TERT
promoter C228T mutation was relatively lower than previous
western studies.10,43 In addition,TERTpromoterC250Tmutation
was not detected. In fact, all of the PTCs in our study subjects
were conventional PTC, which might be the reason of low
frequency in TERT promoter mutations.10
A previous study suggested that the Hh pathway is acti-
vated in PTC, ATC, and follicular adenoma, as demonstrated by
IHC staining to detect SHH, PTCH, SMO, and GLI1.44–46
However, those authors did not detect a correlation between
Hh activation and any clinicopathological parameter. By con-
trast, in this study, we used qRT-PCR to quantitate mRNA
levels in normal and tumor tissues, and then applied the
resultant data to direct comparisons between paired samples.
Through this approach, we could observe changes in Hh path-
way-related gene expression separately in samples from indi-
vidual patients, ultimately allowing us to categorize our study
PTC, GLI1, NFATc4, ABLIM3, and FES are barely detected. In high
IM3 and FES are exclusively located in the cytoplasm. FES¼ feline
IHC¼ immunohistochemical, PTC¼papillary thyroid cancer.subjects into 3 groups according to Hh pathway activity. In
particular, we divided our subjects into 3 groups, with group III
expressing the highest ratio of GLI1 or GLI2 mRNA in PTC
www.md-journal.com | 9
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Lee et al Medicine  Volume 94, Number 25, June 2015relative to normal tissue. Multivariate analyses revealed that
patients in group III for GLI1 and GLI2 exhibited the highest
risk of ETE and LNM, even after adjusting for clinicopatho-
logical parameters. Furthermore, HHIP group III was nega-
tively associated with LNM.
However, genes encoding Hh pathway ligands, such as
SHH, DHH, and IHH, were not valuable as prognostic
indicators, and their expression levels were not related to those
of GLI1, GLI2, and HHIP (data not shown). We postulated that
these negative results reflect the role of the noncanonical GLI
signaling in PTC.47,48 Moreover, GLI1 and GLI2 mRNA
expressions were decreased in PTC compared with matched
normal tissue indicating downregulation of Hh pathway might
be occurred in carcinogenic process in PTC. Whereas, as our
qRT-PCR data indicated, GLI1 and GLI2 group III showed
small increases of mRNA expressions, suggesting the retention
of GLI1 and GLI2 expression and/or the induction of GLI1 and
GLI2 by noncanonical GLI signaling might be an important
event in promoting more aggressive behavior in PTC. Indeed,
although our correlation analyses using the TCGA data did not
any correlation of the GLI1/2 mRNA expressions with AKT1
and mTOR1 expressions, recent molecular biological studies
have revealed crosstalk between GLI signaling and the PI3K-
AKT/mTOR pathways.49,50 Because the mRNA expressions of
AKT1 and mTOR1 cannot be representative makers for AKT1
FIGURE 5. Correlation analyses of GLI1 (A-K) and GLI2 (L-T) with
Genome Atlas Research Network. GLI1¼glioma-associated oncogand mTOR1 activities, future studies need to be conducted to
investigate the relationship of GLI signaling with the PI3K-
AKT/mTOR pathways in PTC. Furthermore, TGFb and
10 | www.md-journal.comconstitutively active Kirsten rat sarcoma viral oncogene homo-
log have been reported to activate Hh signaling.51
In addition, our GSEA using data derived from a public
repository revealed that GLI1 expression is coordinately
regulated along with genes involved in axon guidance. Con-
sistent with this, qRT-PCR data from our patients consistently
indicated thatGLI1 expression was closely related to expression
of axon guidance genes such as ABLIM3, NFATc4, L1CAM,
SEMA3D, FES, PLXNB3, SEMA6A, SEMA6B, ROBO3, and
EPHA8 as further validated by IHC staining and the TCGA data
analyses. These data suggest that GLI1 might be able to
facilitate the EMT by inducing genes related to axon guidance.
Supporting our idea, the mRNA expressions of the EMT
markers such as CDH1 and VIM were accordingly related to
the GLI1/2 expressions. Furthermore, our GSEA indicated that
gene sets involved in neuroactive ligand–receptor interactions,
cytokine–cytokine receptor interactions, and the Notch signal-
ing pathways were also coordinately upregulated in association
with GLI1 expression, suggesting these pathways might be
involved in ETE and LNM in the context of GLI1-driven
EMT. In the case of GLI2, the GSEA analysis using same data
sets presented coordinately enrichment of gene sets involved in
ribosome, DNA replication and pentose phosphate pathways
suggesting sustained proliferative signaling (data not shown).
Taken together, although we could not investigate the GLI1 and
on guidance genes using public repository data from The Cancer
homolog 1, GLI2¼glioma-associated oncogene homolog 2.GLI2 expressions in the invasive front because of the ethical
issues of our institute,33,52 all of our data from qRT-PCR, IHC,
GSEA, statistical analyses using the TCGA data and our cohort
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 5. Analysis of the Association of T Stage and LNM With GLI1 and GLI2 mRNA Levels Using Public Data From The Cancer
Genome Atlas Research Network
mRNA Expression
I (n¼ 168) II (n¼ 168) III (n¼ 168) P
GLI1
Age, y, mean SD 46.0 14.9 48.2 16.1 47.5 16.0 0.432
T stagey 0.048§
T1 or T2 110 (66.3%) 105 (66.0%) 88 (54.7%)
T3 or T4 56 (33.7%) 54 (34.0%) 73 (45.3%)
LNMz 0.039§
Absent 79 (55.6%) 77 (54.2%) 66 (42.3%)
Presence 63 (44.4%) 65 (45.8%) 90 (57.7%)
GLI2
Age, y, mean SD 47.5 14.6 47.1 15.7 47.1 16.6 0.971
T stagejj 0.352§
T1 or T2 108 (65.9%) 97 (60.2%) 98 (60.9%)
T3 or T4 56 (34.1%) 64 (39.8%) 63 (39.1%)
LNM 0.002§
Absent 81(58.7%) 80 (53.0%) 61 (40.4%)
Presence 57 (41.3%) 71 (47.0%) 90 (59.6%)
ANOVA¼Analysis of variance,GLI1¼ glioma-associated oncogene homolog 1, LNM¼ lymph nodemetastasis, mRNA¼Messenger ribonucleic
acid.
P values were calculated by 1-way ANOVA.
yT stage could not be assessed in 18 of 504 cases.
zLNM could not be assessed in 64 of 504 cases.
§P values were calculated by x2 or linear-by-linear association.
Medicine  Volume 94, Number 25, June 2015 GLI1 Expression in Papillary Thyroid Cancersconsistently indicated that GLI1 and GLI2 expressions are
linked to EMT and tumor progressions.
In summary, activation of the Hh pathway, as represented
by GLI1 and GLI2 mRNA expression, predicts ETE and LNM
and can therefore be considered a marker of poor prognosis.
Future studies should investigate the molecular mechanisms
underlying activation of GLI-mediated transcription in PTC,
and the GLI proteins should be validated as novel drug targets.
In addition, the noncanonical mechanisms of Hh pathway
activation should be elucidated to improve our understanding
of carcinogenesis in PTC.
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